San Donato Hospital
| Italia | Turchia | Austria | |
| Tomoterapia | da $32,000 | da $12,000 | da $30,000 |
| Terapia con protoni | da $70,000 | da $70,000 | da $80,000 |
| Sistema robotico Da Vinci | da $18,000 | da $9,500 | da $22,000 |
| Radioterapia per il carcinoma polmonare | da $13,500 | da $4,000 | da $6,964 |
| Radiochirurgia stereotassica | da $25,000 | da $4,500 | da $17,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Tumore al polmone. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Tumore al polmone e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Tumore al polmone.
Il dottore è Professore Associato di Chirurgia Toracica e membro del Consiglio Europeo di Chirurgia Toracica e Cardiovascolare. Come Capo dell'Unità Funzionale Responsabile della Chirurgia Toracica Mini-Invasiva presso il Dipartimento Cardio-Toraco-Vascolare dell'Istituto San Raffaele, il dottore si specializza nel trattamento delle malattie polmonari e pleuriche, nonché dei disturbi mediastinici.<\/p>
Il dottore è affiliato alla Società Italiana di Chirurgia Toracica e alla Società Italiana di Endoscopia Toracica. Con un robusto contributo accademico, il dottore ha scritto una monografia e oltre 200 pubblicazioni scientifiche in riviste nazionali e internazionali.<\/p>
Il medico è il capo del Dipartimento di Radioterapia presso l'Ospedale di Ricerca San Raffaele di Milano, posizione che ricopre dal 2008. Con un focus su metodi di ipofrazionamento ad alta precisione per i tumori della prostata, il medico è il coordinatore italiano del Gruppo Italiano di Brachiterapia dal 1999. In precedenza, il medico ha guidato l'Unità Funzionale di Tomoterapia e ha servito come oncologo radioterapico senior nello stesso ospedale.<\/p>
I successi educativi includono una laurea in medicina generale e chirurgia e una specializzazione in radioterapia oncologica presso l'Università di Milano. Il medico ha scritto 200 studi in oncologia radioterapica ed è membro di diverse società oncologiche prestigiose.<\/p>
Italy offers world-class lung cancer treatment at specialized IRCCS-accredited research hospitals in Milan and Rome. Leading centers like San Raffaele and the European Institute of Oncology provide multidisciplinary care. They utilize advanced robotic thoracic surgery and high-precision radiotherapy to treat complex pulmonary tumors.
Bookimed Expert Insight: Italian IRCCS-accredited centers are unique because they legally must combine clinical care with research. This ensures patients get access to experimental protocols before they go mainstream. For example, San Raffaele was the first to implement specific stem cell therapies. This integration often leads to higher success rates in rare or resistant lung cancer cases.
Patient Consensus: Patients note that major tumor institutes in Milan and Rome offer exceptional expertise. Many recommend securing an EU health card early to help manage the logistics of decentralized care.
Italian oncology centers utilize robotic systems, high-precision radiation, and molecular therapies to treat lung cancer. Facilities like San Raffaele in Milan employ the da Vinci Xi robotic system for minimally invasive thoracic surgery. This approach reduces recovery times and improves surgical precision for complex lung resections.
Bookimed Expert Insight: While many countries offer standard radiation, Italian research hospitals like San Raffaele integrate Tomotherapy with high-precision hypofraction methods. Professor Nadia Di Muzio coordinates specialized protocols that deliver more intense radiation in fewer sessions. This combination is particularly effective for patients requiring both surgical and radiological interventions in a single treatment plan.
Patient Consensus: Patients often choose clinics in Northern Italy to access proton therapy and robotic surgery faster than through public waitlists. Many note that advanced molecular testing is the key first step to qualifying for the latest targeted therapy trials.
Immunotherapy and targeted therapies are widely available for lung cancer in Italy. These treatments are standard for non-small cell lung cancer (NSCLC). Public hospitals and specialized oncology centers provide them through the national health system. Access follows approval by the Italian Medicines Agency.
Bookimed Expert Insight: Expert centers in Milan and northern Italy handle high patient volumes. San Raffaele alone performs over 52,000 operations annually across all departments. This high surgical and clinical volume often correlates with faster access to molecular testing. Patients can benefit from integrated research and clinical practice at these major institutions.
Patient Consensus: Patients note that getting molecular testing early is vital for unlocking targeted options. While coverage is available nationwide, many share that traveling to northern oncology centers often reduces waiting times.
The 5-year survival rate for lung cancer in Italy is approximately 16% for men and 23% for women. Early diagnosis drastically improves outcomes. Stage I localized tumors show survival rates up to 90%. Advanced stage IV cases typically range between 6% and 10% survival.
Bookimed Expert Insight: Clinical data from centers like San Raffaele in Milan confirms that high-volume surgical expertise impacts outcomes. Associate Professor Dr. Giampiero Negri specializes in mini-invasive thoracic surgery for lung diseases. This approach often leads to faster recovery times compared to traditional open chest surgeries. San Raffaele performs over 52,000 operations annually. This high patient volume is a key quality indicator for complex oncology cases.
Patient Consensus: Patients note that early genetic testing for mutations like EGFR is essential. Accessing targeted therapies like osimertinib in Northern Italian hospitals can significantly extend life expectancy.
International medical tourists face significant legal and clinical barriers when enrolling in lung cancer clinical trials in Italy. While major research centers like San Raffaele in Milan operate as global oncology hubs, most trials require Italian residency or an EU health card. Non-EU patients must navigate strict AIFA regulations and complex medical visa requirements.
Bookimed Expert Insight: While Italy is a leader in thoracic research, its trial system is not traditionally designed for medical tourists. San Raffaele in Milan performs over 52,000 operations annually and holds prestigious IRCCS accreditation. However, patients without EU citizenship often find easier trial access in Germany or Switzerland. These neighboring countries frequently provide more robust infrastructure for international trial participants and English-speaking coordinators.
Patient Consensus: Patients note that paperwork for non-EU citizens can be nearly impossible to complete for clinical trials. Many suggest checking eligibility directly with trial sponsors before traveling to Milan or Rome to avoid rejection.